  Bone marrow transplant The safety and efficacy of Caphosol has been demonstrated in a double-blind prospective, randomized clinical trial in patients undergoing bone marrow transplantation. This trial demonstrated that Caphosol, used in conjunction with fluoride treatments, offers significant benefits over standard care, and is a significant adjunct in the management of oral mucositis associated with high-dose chemotherapy and radiation therapy. In this study the duration and severity of oral mucositis, and requirements for opioid medication, were evaluated in 95 patients undergoing bone marrow transplantation. The treatment arm received 4 topical fluoride treatments plus Caphosol, while the control arm received a fluoride rinse (0.01\% NaF aqueous solution). Patients were instructed to rinse 4 times per day at the start of cancer treatment and up to 10 times per day if they developed severe oral mucositis. The results showed:  &  &  &  &  Using Caphosol Caphosol is a preparation comprising two separately packaged aqueous solutions, a phosphate solution (Caphosol A) and a calcium solution (Caphosol B) which, when combined in equal volumes, forms a supersaturated solution of both  calcium and phosphate ions. Caphosol is usually used 4 times a day, but can be used up to 10 times a day when symptoms of mucositis are present. Caphosol is usually used for the duration of cancer treatment, unless directed otherwise by a physician. Please note that caphosol is used as an oral rinse and is therefore not "taken". (It is not dangerous/harmful if consumed but consumption should be avoided, according to the manufacturer.)
There is a lack of good quality evidence for the efficacy of caphosol solution and the only systematic review is funded by the manufacturer and so carries an increased risk of bias.Quinn, B. (2013). Efficacy of a supersaturated calcium phosphate oral rinse for the prevention and treatment of oral mucositis in patients receiving high‐dose cancer therapy: a review of current data. European journal of cancer care, 22(5), 564-579. Quality evidence for Caphosol effervescent tablets is lacking. Bone marrow transplant The safety and efficacy of Caphosol has been demonstrated in a double-blind prospective, randomized clinical trial in patients undergoing bone marrow transplantation. This trial demonstrated that Caphosol, used in conjunction with fluoride treatments, offers significant benefits over standard care, and is a significant adjunct in the management of oral mucositis associated with high-dose chemotherapy and radiation therapy. In this study the duration and severity of oral mucositis, and requirements for opioid medication, were evaluated in 95 patients undergoing bone marrow transplantation. The treatment arm received 4 topical fluoride treatments plus Caphosol, while the control arm received a fluoride rinse (0.01\% NaF aqueous solution). Patients were instructed to rinse 4 times per day at the start of cancer treatment and up to 10 times per day if they developed severe oral mucositis. The results showed: Cancer Therapy Mucositis in Children A a prospective multicenter double blind randomized controlled trial showed no advantages for caphosol and statistically significantly more days of pain and analgesia use for the caphosol arm.Raphaël, Martine Boer, A& Kollen, Wouter Mekelenkamp, Hilda& Abbink, Floor Kaspers, G& Zomer-Kooijker, Kim Molmans, B& Tissing, Wim. (2013). Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children? Results from a prospective multicenter double blind randomized controlled trial. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 22. 10.1007/s00520-013-2015-0. Using Caphosol Caphosol refers to two different preparations. An effervescent dispersible tablet or two separately packaged aqueous solutions, a phosphate solution (Caphosol A) and a calcium solution (Caphosol B) which, when combined in equal volumes, forms a supersaturated solution of both calcium and phosphate ions. It is doubtful that the effervescent tablet can achieve a supersaturated solution of calcium and phosphate ions. Caphosol is usually used 4 times a day, but can be used up to 10 times a day when symptoms of mucositis are present. Caphosol is usually used for the duration of cancer treatment, unless directed otherwise by a physician. Please note that caphosol is used as an oral rinse and is therefore not "taken". (It is not dangerous/harmful if consumed but consumption should be avoided, according to the manufacturer.)
A
There is a lack of good quality evidence for the efficacy of caphosol solution and the only systematic review is funded by the manufacturer and so carries an increased risk of bias.Quinn, B. (2013). Efficacy of a supersaturated calcium phosphate oral rinse for the prevention and treatment of oral mucositis in patients receiving high‐dose cancer therapy: a review of current data. European journal of cancer care, 22(5), 564-579.
A
Quality evidence for Caphosol effervescent tablets is lacking.
A
Cancer Therapy Mucositis in Children A a prospective multicenter double blind randomized controlled trial showed no advantages for caphosol and statistically significantly more days of pain and analgesia use for the caphosol arm.Raphaël, Martine
A
Boer, A
A
Kollen, Wouter
A
Mekelenkamp, Hilda
A
Abbink, Floor
A
Kaspers, G
A
Zomer-Kooijker, Kim
A
Molmans, B
A
Tissing, Wim. (2013). Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children? Results from a prospective multicenter double blind randomized controlled trial. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 22. 10.1007/s00520-013-2015-0.
R
is a preparation comprising two
refers to two different preparations. An effervescent dispersible tablet or two
A
calcium and phosphate ions. It is doubtful that the effervescent tablet can achieve a supersaturated solution of